Kalaris Therapeutics (KLRS) director receives 9,000-stock option grant

Rhea-AI Filing Summary

Kalaris Therapeutics director Srinivas Akkaraju received a grant of options to buy 9,000 shares of common stock on June 3, 2026. The options have an exercise price of $4.72 per share and expire on June 2, 2036. The underlying 9,000 shares are scheduled to vest in full on the earlier of June 3, 2027 or the company’s 2027 Annual Meeting of Stockholders, subject to continued service. After this grant, the filing shows Akkaraju holding 9,000 stock options directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider AKKARAJU SRINIVAS

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	9,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 9,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 9,000 options Exercise price: $4.72 per share Underlying shares: 9,000 shares +3 more

6 metrics

Option grant size 9,000 options Grant to director on June 3, 2026

Exercise price $4.72 per share Stock option exercise price

Underlying shares 9,000 shares Common stock underlying the options

Expiration date June 2, 2036 Option expiration

Vesting date trigger June 3, 2027 or 2027 meeting Earlier of these dates, subject to continued service

Holdings after grant 9,000 options Total stock options held directly post-transaction

Key Terms

Stock Option (Right to Buy), vest in full, Annual Meeting of Stockholders, Grant, award, or other acquisition

4 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

vest in full financial

"shares underlying the option are scheduled to vest in full"

Annual Meeting of Stockholders financial

"the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service"

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AKKARAJU SRINIVAS

(Last) (First) (Middle)

C/O KALARIS THERAPEUTICS, INC.

400 CONNELL DRIVE, SUITE 5500

(Street)

BERKELEY HEIGHTS NEW JERSEY 07922

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kalaris Therapeutics, Inc. [ KLRS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.72	06/03/2026		A		9,000		(1)	06/02/2036	Common Stock	9,000	$0	9,000	D

Explanation of Responses:

1. The option was granted on June 3, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 3, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

	/s/ Brett Hagen, Attorney-in-Fact	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Kalaris Therapeutics (KLRS) director Srinivas Akkaraju receive in this Form 4?

Director Srinivas Akkaraju received a grant of stock options for 9,000 shares of Kalaris Therapeutics common stock. These options are a compensation award, not an open-market share purchase or sale, and give him the right to buy shares at a fixed exercise price.

What is the exercise price and size of the KLRS stock options granted to Akkaraju?

The grant covers 9,000 shares of Kalaris Therapeutics common stock at an exercise price of $4.72 per share. This means he can purchase those shares at $4.72 regardless of the market price when he exercises, once vesting conditions are met.

When do Srinivas Akkaraju’s Kalaris Therapeutics options vest?

The 9,000-share option grant is scheduled to vest in full on the earlier of June 3, 2027 or the date of Kalaris Therapeutics’ 2027 Annual Meeting of Stockholders. Vesting is explicitly subject to his continued service with the company through that vesting date.

When do the KLRS stock options granted to Akkaraju expire?

The stock options granted to Srinivas Akkaraju expire on June 2, 2036. After that expiration date, any unexercised options become worthless, so he must exercise vested options before then if he chooses to acquire the underlying shares.

Are these KLRS option transactions open-market buys or sells?

No, this Form 4 reflects a compensation-related grant of stock options, coded as a grant, award, or other acquisition. It does not show any open-market purchase or sale of Kalaris Therapeutics common shares by Srinivas Akkaraju.

How many Kalaris Therapeutics options does Akkaraju hold after this grant?

After this transaction, the Form 4 reports that Srinivas Akkaraju holds 9,000 stock options directly. These options correspond to 9,000 underlying shares of Kalaris Therapeutics common stock, all subject to the vesting schedule described in the footnote.